Atresia Bilier

01Pathophysiology

Biliary atresia is a progressive fibro-obliterative cholangiopathy that targets the extrahepatic bile ducts and, if untreated, inevitably leads to biliary cirrhosis. The disease involves inflammatory destruction and fibrotic obliteration of part or all of the extrahepatic biliary system, resulting in complete obstruction to bile flow.

The prevailing theory centers on a two-hit model. The first hit is thought to be a perinatal viral infection (most commonly implicated agents include reovirus, rotavirus, and cytomegalovirus) that damages the bile duct epithelium. This initial insult triggers the second hit: an aberrant immune-mediated response in which autoreactive T cells and proinflammatory cytokines attack the biliary epithelial cells. This leads to progressive periductal inflammation, fibrosis, and ultimately complete luminal obliteration of the extrahepatic ducts.

Once the bile ducts are obliterated, conjugated bilirubin cannot be excreted into the intestine. This is the direct pathophysiologic explanation for the clinical triad: conjugated bilirubin backs up into the bloodstream causing jaundice, the absence of bile pigment in stool produces acholic (clay-colored) stools, and conjugated bilirubin filtered by the kidneys produces dark urine. Because bile salts also fail to reach the intestinal lumen, fat malabsorption develops, leading to deficiencies of fat-soluble vitamins (A, D, E, K) and failure to thrive.

If bile flow is not restored, the ongoing cholestasis causes progressive hepatic fibrosis and biliary cirrhosis, ultimately resulting in portal hypertension, hepatic synthetic failure, and death within the first two years of life without intervention. This is precisely why biliary atresia remains the most common indication for liver transplantation in the pediatric population.

02Classification and Clinical Manifestation

Morphologic Classification (by Site of Obstruction)

Clinical Subtypes

Clinical Manifestation by Stage

03Diagnostic Workup

The most important first step when evaluating a jaundiced neonate beyond 2 weeks of age is to obtain a fractionated bilirubin. Any infant with jaundice persisting past 14 days of life must have their total and direct bilirubin measured. The finding of conjugated hyperbilirubinemia (direct bilirubin > 1.0 mg/dL) is never physiologic and demands urgent evaluation. This single principle is tested repeatedly: physiologic jaundice is always unconjugated, and conjugated hyperbilirubinemia in a neonate is pathologic until proven otherwise.

Once conjugated hyperbilirubinemia is confirmed, the best initial imaging study is an abdominal ultrasound. The ultrasound serves two purposes: it looks for the classic features of biliary atresia (absent gallbladder, triangular cord sign) and it excludes structural causes of obstruction such as a choledochal cyst. An infant who is fasting and still shows a contracted or absent gallbladder on ultrasound raises strong suspicion for biliary atresia.

If ultrasound is suggestive, a HIDA scan (hepatobiliary scintigraphy) is performed next. The hallmark finding is normal hepatic uptake of the radiotracer but absolutely no excretion into the intestine at 24 hours. To improve the sensitivity of this test and reduce false positives (where severe neonatal hepatitis could also show poor excretion), phenobarbital is administered orally for 5 days prior to the scan. Phenobarbital induces hepatic enzymes and enhances bile flow, so if the ducts are patent (as in neonatal hepatitis), excretion will improve; if the ducts are obliterated (as in biliary atresia), no excretion will occur regardless.

A percutaneous liver biopsy often follows to further support the diagnosis. The classic histologic pattern of biliary atresia includes bile ductular proliferation and portal tract fibrosis, which differs from the pattern seen in neonatal hepatitis (lobular disarray and giant cell transformation).

The gold standard for confirmation is the intraoperative cholangiogram, performed during surgical exploration. If contrast fails to fill the biliary tree, the diagnosis is confirmed, and the surgeon proceeds directly with a Kasai portoenterostomy in the same operative session.

04Management and Treatment

Acute management centers on surgical intervention. The Kasai portoenterostomy is the cornerstone of treatment and must be understood as a bridge procedure, not a cure. During the operation, the surgeon excises the fibrotic extrahepatic biliary remnant up to the level of the porta hepatis and anastomoses a Roux-en-Y loop of jejunum directly to the exposed surface of the liver at the porta hepatis. The goal is to allow residual microscopic bile ductules at the cut surface to drain bile into the intestinal lumen.

Timing is critical. The success rate of Kasai is directly correlated with the age at surgery. When performed before 60 days of life, approximately 60-70% of infants will achieve adequate bile drainage (defined by clearance of jaundice). Success drops significantly after 90 days due to the irreversible progression of intrahepatic fibrosis and cirrhosis. This timing principle is among the most testable concepts in biliary atresia.

Post-Kasai management includes ursodeoxycholic acid to promote bile flow, fat-soluble vitamin replacement to address malabsorption, MCT-enriched formulas for caloric support, and prophylactic antibiotics to prevent ascending cholangitis (one of the most common post-operative complications).

Long-term management involves close surveillance for complications of progressive liver disease. Even with a successful Kasai procedure, many patients develop progressive intrahepatic fibrosis over years to decades. Liver transplantation is ultimately required in the majority of patients and represents the definitive treatment. Biliary atresia accounts for approximately 40-50% of all pediatric liver transplantations worldwide.

Contraindications and caveats: There are no absolute medical contraindications to the Kasai procedure itself, but patients presenting after 120 days of life with established cirrhosis may be triaged directly to transplant evaluation, as the likelihood of Kasai success is extremely low. Corticosteroid use post-Kasai remains debated, and current evidence does not strongly support routine postoperative steroid administration.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The single most common trap with biliary atresia questions involves failing to distinguish conjugated from unconjugated hyperbilirubinemia. A vignette will describe a 3- to 6-week-old infant with persistent jaundice, and the test-writer is checking whether you recognize that jaundice beyond 2 weeks in a full-term infant requires a fractionated bilirubin. Many students default to reassurance ("it's just physiologic" or "it's breast milk jaundice") because the infant looks otherwise well. The critical teaching point: physiologic jaundice and breast milk jaundice are always unconjugated, while biliary atresia produces conjugated hyperbilirubinemia. The moment the vignette mentions pale or clay-colored stools, dark urine, or a direct bilirubin that is elevated, biliary atresia must be at the top of the differential.

The second major trap is confusing biliary atresia with neonatal hepatitis on the HIDA scan. Both conditions can show poor hepatic excretion, but the key is phenobarbital pretreatment: in neonatal hepatitis, phenobarbital priming restores some intestinal excretion, while in biliary atresia, there is absolutely no excretion regardless of pretreatment. A vignette that mentions a HIDA scan "without prior phenobarbital administration" showing no excretion is deliberately ambiguous and should prompt the student to recognize the need for phenobarbital priming before interpreting the scan as diagnostic.

The third pearl concerns the urgency of the Kasai procedure. Questions may present a patient diagnosed at various ages to test whether you know the critical window. If the infant is under 60 days old, the answer is Kasai portoenterostomy. If the infant is beyond 90-120 days with established cirrhosis, the answer shifts toward liver transplant evaluation. The core competency being tested is your ability to recognize biliary atresia early, order the correct workup in the right sequence, and understand that delayed diagnosis directly worsens prognosis.

Finally, remember that biliary atresia is not the same as "biliary hypoplasia." Alagille syndrome is characterized by a paucity (too few) of intrahepatic bile ducts, while biliary atresia involves obliteration and fibrosis of extrahepatic ducts with ductular proliferation on biopsy. This histologic distinction (proliferation vs. paucity) is a favorite discriminator on exams.